Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Offering
Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Antibe Therapeutics Inc. (TSXV: ATE) ("Antibe" or the "Company") announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the "Units") at a price of $0.40 per Unit (the "Offering Price") plus the exercise in full of the Underwriters' over-allotment option of 9,375,000 units for aggregate gross proceeds of $28,750,000 (the "Offering"). The Offering was made pursuant to an underwriting...
2020-06-30 9:33 AM EDT
IIROC Trade Resumption - Antibe Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - May 25, 2017) - Trading resumes in: Company: Antibe Therapeutics Inc.
2017-05-25 8:44 AM EDT
IIROC Trade Halt - Antibe Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2017) - The following issues have been halted by IIROC: Company:
2017-05-24 1:14 PM EDT
IIROC Trade Resumption - Antibe Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2017) - Trading resumes in: Company: Antibe Therapeutics Inc.
2017-02-24 11:08 AM EST
IIROC Trade Halt - Antibe Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2017) - The following issues have been halted by IIROC: Company:
2017-02-24 10:07 AM EST
IIROC Trade Halt - Antibe Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2015) - The following issues have been halted by IIROC: Company:
2015-10-06 8:04 AM EDT